Afficher la notice abrégée

dc.creatorSlart R.H.J.A., Glaudemans A.W.J.M., Gheysens O., Lubberink M., Kero T., Dweck M.R., Habib G., Gaemperli O., Saraste A., Gimelli A., Georgoulias P., Verberne H.J., Bucerius J., Rischpler C., Hyafil F., Erba P.A.en
dc.date.accessioned2023-01-31T09:58:04Z
dc.date.available2023-01-31T09:58:04Z
dc.date.issued2021
dc.identifier10.1093/ehjci/jeaa299
dc.identifier.issn20472404
dc.identifier.urihttp://hdl.handle.net/11615/79124
dc.description.abstractWith this summarized document we share the standard for positron emission tomography (PET)/(diagnostic)computed tomography (CT) imaging procedures in cardiovascular diseases that are inflammatory, infective, infiltrative, or associated with dysfunctional innervation (4Is) as recently published in the European Journal of Nuclear Medicine and Molecular Imaging. This standard should be applied in clinical practice and integrated in clinical (multicentre) trials for optimal standardization of the procedurals and interpretations. A major focus is put on procedures using [18F]-2-fluoro-2-deoxyglucose ([18F]FDG), but 4Is PET radiopharmaceuticals beyond [18F]FDG are also described in this summarized document. Whilst these novel tracers are currently mainly applied in early clinical trials, some multicentre trials are underway and we foresee in the near future their use in clinical care and inclusion in the clinical guidelines. Diagnosis and management of 4Is related cardiovascular diseases are generally complex and often require a multidisciplinary approach by a team of experts. The new standards described herein should be applied when using PET/CT and PET/magnetic resonance, within a multimodality imaging framework both in clinical practice and in clinical trials for 4Is cardiovascular indications. VC The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.en
dc.language.isoenen
dc.sourceEuropean Heart Journal Cardiovascular Imagingen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85096948238&doi=10.1093%2fehjci%2fjeaa299&partnerID=40&md5=f0ef9f0487fa0fd2b2ba8c0225ea6610
dc.subjectfluorodeoxyglucose f 18en
dc.subjectradiopharmaceutical agenten
dc.subjectblood vessel graften
dc.subjectcardiac sarcoidosisen
dc.subjectcardiovascular diseaseen
dc.subjectclinical practiceen
dc.subjectdevice infectionen
dc.subjectgraft infectionen
dc.subjectheart amyloidosisen
dc.subjecthumanen
dc.subjectimage analysisen
dc.subjectlarge vessel vasculitisen
dc.subjectpositron emission tomography-computed tomographyen
dc.subjectpractice guidelineen
dc.subjectpriority journalen
dc.subjectprosthesis complicationen
dc.subjectprosthetic valve endocarditisen
dc.subjectquantitative analysisen
dc.subjectReviewen
dc.subjectstandardized uptake valueen
dc.subjectcardiovascular diseaseen
dc.subjectdiagnostic imagingen
dc.subjectpositron emission tomographyen
dc.subjectstandarden
dc.subjectCardiovascular Diseasesen
dc.subjectFluorodeoxyglucose F18en
dc.subjectHumansen
dc.subjectPositron Emission Tomography Computed Tomographyen
dc.subjectPositron-Emission Tomographyen
dc.subjectRadiopharmaceuticalsen
dc.subjectReference Standardsen
dc.subjectOxford University Pressen
dc.titleProcedural recommendations of cardiac PET/ CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation- (4Is) related cardiovascular diseases: a joint collaboration of the EACVI and the EANM: summaryen
dc.typeotheren


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée